Australia Cancer Pain Management Market Report 2022 to 2030

Australia Cancer Pain Management Market Analysis

$ 3999

Australia's Cancer Pain Management market is projected to grow from $78.24 Mn in 2022 to $132.43 Mn by 2030, registering a CAGR of 6.8% during the forecast period of 2022-2030. The main factors driving the growth would be as growing private healthcare sector, aging population, government initiatives, and increasing cancer incidence. The market is segmented by drug type and by disease. Some of the major players include Little Green Pharma (AUS), Phebra (AUS), Pfizer, Teva Pharmaceuticals, and Sanofi

ID: IN10AUHS002 CATEGORY: Healthcare Services GEOGRAPHY: Australia AUTHOR: Neha Davda

Buy Now

Australia Cancer Pain Management Market Executive Summary

Australia's Cancer Pain Management market is projected to grow from $78.24 Mn in 2022 to $132.43 Mn by 2030, registering a CAGR of 6.8% during the forecast period of 2022–30. In Australia, $202.5 billion, or $7,926 per person, was spent on healthcare overall in 2019–20. The real rise in healthcare spending was 1.8%, which was less than the 3.4% of the decade average. The majority of the funding for healthcare in Australia comes from the government, but patients are also footing a larger share of the spending.

A number of well-known acute and persistent pain disorders are connected to cancer. Cancer results in gene changes impacting vital cell-regulatory proteins. These modifications promote abnormal cell behavior, which in turn leads to unrestrained cell growth and the subsequent destruction of nearby normal tissues. These tumors impose pressure on the body and produce discomfort by pressing on bones, nerves, and other parts of the body. Especially in more advanced phases of the illness, cancer discomfort can also be experienced while receiving aggressive cancer therapy. In Australia, cancer is a leading cause of illness and death.

australia cancer pain management

Market Dynamics

Market Growth Drivers

The Australia cancer pain management market is expected to be driven by factors such as the growing private healthcare sector, aging population, government initiatives, and increasing cancer incidence. In Australia, cancer is a leading cause of illness and death. About 151,000 Australians are anticipated to receive a cancer diagnosis in 2021 (413 per day), and 49,000 will pass away from the disease (135 per day).

Market Restraints

Australia has tight regulatory requirements, and it can take some time for novel cancer pain management therapies to receive approval and concerns related to the adverse effects of pain management drugs. This may restrict the availability of novel treatments and restrain the cancer pain management market expansion in the country.

Competitive Landscape

Key Players

Little Green Pharma (AUS)
Phebra (AUS)
Pfizer
Teva Pharmaceuticals
Sanofi

Healthcare Policies and Regulatory Landscape

The Department of Health and the Therapeutic Goods Administration (TGA), are federal agencies that are principally responsible for overseeing the healthcare system in Australia (TGA). The TGA is in charge of overseeing the regulation of therapeutic goods, which includes items for pain management such as prescription drugs, over-the-counter items, and medical equipment.

Australia has several rules in place to restrict pain management, such as the Poisons Standard, which defines banned medications like opioids and specifies the guidelines for their usage. The Pharmaceutical Benefits Scheme (PBS), which chooses which prescription drugs are funded by the government for patient usage, also contributes to the regulation of pain management goods. The practice of medicine and the distribution of prescription drugs are governed by state and territorial laws and regulations also in Australia in addition to federal laws.

Reimbursement Scenario

In Australia, the Pharmaceutical Benefits Scheme (PBS) and the Medical Benefits Schedule (MBS) serve as the primary sources of funding for pain treatment products and services. PBS is a federal government program that helps eligible individuals afford the cost of their prescription medications. A pain treatment product must be on the PBS and meet specific requirements, such as being declared safe and effective by the TGA, in order to be eligible for PBS reimbursement. MBS is a list of medical treatments and services that qualify for reimbursement under the Medicare program. A variety of medical services, including some pain management services like specific diagnostic procedures and specialist consultations, are covered by the MBS.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.